EMA’s CHMP rejects approval of multiple sclerosis drug Nerventra
The two firms said they are committed to the Nerventra clinical development program for multiple sclerosis (MS) and are focused on evaluating the CHMP feedback to determine potential
Mediar Therapeutics has announced a collaboration and option agreement with Ono Pharmaceutical to develop new treatments for fibro-inflammatory diseases.